Investment trusts tap the profits in exotic and obscure global markets
Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money


Unicorn Mastertrust invests exclusively in investment trusts, aiming to deliver an attractive total return primarily in the form of capital growth. Trusts have a long and proud history dating back more than 150 years and have survived every conceivable geopolitical and economic disaster.
Donald Trump’s Liberation Day shenanigans will cause some headaches in the short term, but I am sure that investment companies will continue to serve investors well for decades to come. My confidence stems from a belief that an investment trust offers the best structure for successful investment in the long term. This is quite an assertion given that most fund assets around the world are in open-ended structures rather than closed-ended trusts.
The portfolio has a structural bias towards trusts that use their semi-permanent capital to invest in relatively illiquid assets on a global basis. Consequently, the fund has plenty of exposure to smaller companies (in the UK and overseas), listed private equity (LPE) trusts, and specialist trusts suitable only for a properly diversified portfolio.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Big potential in British small caps
The largest holding in the first category, the Aberforth Smaller Companies Trust (LSE: ASL), is not only the largest trust of its type but also the only one to have a value-investing approach. Applied consistently since launch in 1990, this investment style experienced a protracted period of underperformance in the low-interest rate period following the global financial crisis.
A further headwind for the portfolio, which comprises around 80 UK smaller companies, came with the Brexit vote, followed by an accelerating shift of capital towards the American growth story. The fundamental ratings of ASL’s investments became so cheap that corporate buyers were attracted to the market, leading to a surge in mergers and acquisitions, which looks set to endure.
The ICG Enterprise Trust (LSE: ICGT) is an LPE trust that invests in buyouts in North America and Europe. Typically, these investments in private companies would be expected to be realised or refinanced within a period of between five and seven years, but sales have been somewhat elusive over the last couple of years. Questions have therefore been raised about the validity of the valuations of LPE trusts, and Mr. Market has ruled on the issue by pushing discounts to net asset value (NAV) ever wider.
As a result, over the last five years, ICGT’s NAV has expanded at a compound annual growth rate (CAGR) of 13.8%, while the share price’s CAGR has been only 8.5%. The discount to NAV has reached a staggering 37%. Earlier this month, the managers announced the sale of around 5% of the portfolio at a level that provided strong validation of the NAV and released capital for new investments and share buybacks.
Go for gold
Gold is globally fungible and difficult to apply tariffs to. Its price can also be volatile, so my selection in the specialist trust category comes with a bumper wealth warning. Golden Prospect Precious Metals (LSE: GPM) invests in gold and precious metals companies.
The fund’s effective exposure to gold miners is 91%, with the balance in silver producers. If fears of tariff-driven stagflation and interest rates staying higher for longer prove right, and inflows continue into physical exchange-traded funds (ETFs), GPM could be one to watch.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Peter Walls is fund manager of the Unicorn Mastertrust Fund.
-
HMRC confirms crypto ETN ISA rules
With crypto ETNs now technically available for UK retail investors, HMRC has confirmed they can be held in an ISA – but there’s a complication
-
Pensioners targeted in fine wine scams – the tactics to watch for
Wine has emerged as the latest lure in investment fraud, with pensioners being specifically targeted by scammers
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?